Clinical Trial

A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

Study acronym: CABOTEM
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of CABOTEM study is to demonstrate the safety and activity of the Cabozantinib and Temozolomide combination in Lung and GEP-NENs patients, progressing after a first line therapy, including target therapies (everolimus, sunitinib) and / or chemotherapy, in the approved setting.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-05-14; most recent amendment 2024-06-17.
Status change: Not Yet Recruiting → Recruiting 2021-10-12
Trial Details
NCT Number NCT04893785
Lead Sponsor National Cancer Institute, Naples
Conditions Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor
Enrollment 35 participants
Start Date 2021-06-15
Primary Completion 2025-01 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-06-18